Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland; CY Cergy Paris Université, Biomaterials for Health group, ERRMECe, Neuville sur Oise, France.
Acta Biomater. 2024 Sep 15;186:489-506. doi: 10.1016/j.actbio.2024.07.053. Epub 2024 Aug 2.
Commercially available bioactive glasses (BAGs) are exclusively used in powder form, due to their tendency to crystallize. Silicate BAG 1393 was developed to allow fiber drawing and scaffold sintering, but its slow degradation limits its potential. To enable scaffold manufacturing while maintaining glass dissolution rate close to that of commercially available BAGs, the borosilicate glass 1393B20 was developed. This study investigates the potential of 1393B20 scaffolds to support bone regeneration and mineralization in vitro and in vivo, in comparison to silicate 1393. Both scaffolds supported human adipose stem cells proliferation, either in direct contact for the 1393, or mainly around for the 1393B20. Similarly, both BAGs induced osteogenesis and angiogenesis in vitro, with a better pro-angiogenic influence of the 1393B20. In addition, these scaffolds supported bone regeneration and osteoclast/osteoblast activity in vivo in critical-sized rat calvarial defect. Nevertheless, mineralization and collagen formation were significantly enhanced for the 1393B20, at 3-months post-implantation, assigned to faster and more complete dissolution of the scaffolds. Thus, 1393B20 demonstrates greater promise for bone tissue engineering certainly due to its time-controlled release of boron and silicon. STATEMENT OF SIGNIFICANCE: Bioactive glasses (BAGs) show great promise in bone tissue engineering as they effectively bond with bone tissue, fostering integration and regeneration. Silicate BAG 1393 was developed to allow fiber drawing and scaffold sintering, but its slow degradation limits its potential. To enable scaffold manufacturing while maintaining glass dissolution rate close to that of commercially available BAGs, the borosilicate glass 1393B20 was developed. Both BAGs induced osteogenesis and angiogenesis in vitro, with a better pro-angiogenic influence of the 1393B20. The presence of boron in the 1393B20 enhanced mineralization and collagen formation in vivo compared to 1393, probably due to its faster dissolution rate. Here, 1393B20 demonstrated greater promise for bone tissue engineering compared to the well-known 1393 BAG.
市售的生物活性玻璃（BAGs）由于其结晶倾向，仅以粉末形式使用。开发硅酸盐 BAG 1393 是为了允许纤维拉丝和支架烧结，但它的缓慢降解限制了其潜力。为了在保持玻璃溶解率接近市售 BAG 的情况下实现支架制造，开发了硼硅酸盐玻璃 1393B20。本研究比较了 1393B20 支架在体外和体内支持骨再生和矿化的潜力，与硅酸盐 1393 相比。两种支架都支持人脂肪干细胞的增殖，1393 为直接接触，1393B20 则主要在周围。同样，两种 BAGs 在体外均诱导成骨和血管生成，1393B20 具有更好的促血管生成作用。此外，这些支架在大鼠临界大小颅骨缺损的体内支持骨再生和破骨细胞/成骨细胞活性。然而，在植入后 3 个月，1393B20 的矿化和胶原形成显著增强，这归因于支架更快和更完全的溶解。因此，1393B20 对骨组织工程具有更大的潜力，这肯定是由于其硼和硅的时间控制释放。
生物活性玻璃（BAGs）在骨组织工程中具有很大的应用前景，因为它们能有效地与骨组织结合，促进整合和再生。硅酸盐 BAG 1393 的开发是为了允许纤维拉丝和支架烧结，但它的缓慢降解限制了其潜力。为了在保持玻璃溶解率接近市售 BAG 的情况下实现支架制造，开发了硼硅酸盐玻璃 1393B20。两种 BAGs 在体外均诱导成骨和血管生成，1393B20 具有更好的促血管生成作用。1393B20 中的硼增强了体内的矿化和胶原形成，与 1393 相比，可能是由于其更快的溶解速率。与知名的 1393 BAG 相比，1393B20 显示出在骨组织工程方面有更大的潜力。
